

## ELENCO PUBBLICAZIONI PROF. SOARDO

1. **Soardo G.** Donnini D, Domenis D, Catena C, De Silvestri D, Cappello D, Dibenedetto A, Carnelutti A, Bonasia V, Ppagano C, Sechi LA Oxidative Stress Is Activated by Free Fatty Acids in Cultured Human Hepatocytes. Met Syndr. Related disorders 2011: Oct;9(5):397-401.
2. **Soardo G.** Donnini D, Varutti R, Milocco C, Basan L, Esposito W, Casaccio D, Isola M, Soldano F, Sechi LA, Effects of alcohol withdrawal on blood pressure in hypertensive heavy drinkers. J Hypertension 2006: 24; 1493-1498.
3. **Soardo G.** Donnini D, Moretti M, Milocco C, Catena C, Sechi LA Effects of antihypertensive drugs on alcohol-induced functional responses of cultured human endothelial cells. Hypertension Res 2008: 31; 345-351
4. **Soardo G.** Donnini D, Varutti R, Moretti M, Milocco C, Basan L, Esposito W, Casaccio D, Stel G, Catena C, Curcio F, Sechi LA Alcohol- induced endothelial Changes are associated with oxidative stress and are rapidly reversed after withdrawal. Alcoholism Clin Exp Res. 2005; 29: 1889-1898.
5. **Soardo G.** Basan L, Intini S, Avellini C, Sechi LA Elevated serum CA 19-9 in Hepatic Actinomycosis. Scandinavia J Gastroenterology, 2005; 40: 1372-1373.
6. **Soardo G.** Pirisi M, Fonda M, Fabris C, Falletti E, Toniutto P, Vitulli D, Cattin L, Gonano F, Bartoli E Changes in blood lipid composition and response to interferon treatment in chronic hepatitis C. J Interferon Cytokine Res 1995; 15:705-12.
7. **Soardo G.** Castaldo V, Donnini D, Uzzau A, Pizzolito S, Sechi L.A. Monomorphic epitheliotropic intestinal T cell Lymphoma of the appendix: a case report and review of literature. Journal of Gastrointestinal Cancer 2020 Jun;51(2):688-694
8. **Soardo G.** Pirisi M, Romano G, Bartoli E. Iperlipoproteinemia in corso di sindrome nefrosica: fisiopatologia e nuovi orientamenti terapeutici. Basi Raz Ter 1992; 22:123-34
9. **Soardo G.** Orsaria M, Scatà L, Donnini D, Sechi LA. Hepatoportal Sclerosis in patients with Systemic Sclerosis and Sjögren's Syndrome: a rare association. Journal of Clinical Images and Medical Case Reports. Vol 2 May 2021
10. Da Col PG, **Soardo G.** Zacchi T. HLA antigens in familial hyper-alphalipoproteinemia. Tissue Antigen 27: 244-246; 1986
11. Fabris C, **Soardo G.** Falletti E, Toniutto P, Vitulli D, Federico E, Del Forno M, Matusso M, Gonano F, Pirisi M Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to INF-alpha in chronic hepatitis C. J Interferon Cytokine Res. 1998 Sep; 18(9): 705-9.

12. Furlanut M, **Soardo G**, Donnini D, Sechi LA, De Franceschi L Fluoxetine disposition in patients suffering from chronic hepatitis C treated with interferon alpha. *Clinical Pharmacokinetics. Clin Pharmacokinet* 2010; 49 (11): 767-772
13. Pirisi M, **Soardo G**, Bartoli E. Fisiopatologia dell'equilibrio idrosalino e patogenesi dell'ascite. *Atti della XVII Settimana Nazionale di Epatologia*, Scientific Press. P 140-152:1992
14. Pagano C, **Soardo G**, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R Plasma adiponectin is decreased in nonalcoholic fatty liver disease. *European Journal Endocrinology* 2005; 152: 113-118.
15. Pagano C, **Soardo G**, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M, Avellini C, Federspil G, Sechi LA, Vettor R Increased serum resistin in nonalcoholic fatty liver disease related to liver disease severity and not to insulin resistance. *J Clin Endocrinol Metab* 2006; 91: 1081-1086
16. Quartuccio L, **Soardo G**, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. *Rheumatology* 2006; 45; 842-846.
17. Catena C, **Soardo G**, Melis A, De Marchi S, Sechi LA Glucose metabolism in early renal failure. *Am J Kidney Dis.* 2005; 46; 367-369.
18. Pirisi M, **Soardo G**. Chemotherapy-induced acral erythema. *N Engl J Med* 1994; 30:1279.
19. Pirisi M, **Soardo G**, Romano G, Bartoli E. Significato e valore diagnostico dei sintomi e degli esami di laboratorio. *Fed Med* 45:11-16, 1992.
20. Toniutto P, **Soardo G**, Fabris C, Pirisi M. Basi razionali di terapia nell'asma bronchiale cronica. *Il Friuli Medico - Alpe Adria Journal of Medicine*, 48:329-341, 1993.
21. C.Catena, G. Colussi, N. D. Verheyen, M. Novello, V. Fagotto, **G. Soardo**, L. A. Sechi Moderate Alcohol Consumption Is Associated With Left Ventricular Diastolic Dysfunction in Nonalcoholic Hypertensive Patients. *Hypertension* 2016
22. Valenti L, Motta M.B., **Soardo G**, Iavarone M, Bertelli C, Sangiovanni A, Carnelutti A, Dongiovanni P, Rametta R, Donati B, Colombo M, Fargion S, Fracanzani AL, PNPLA3 I148M polymorphism, clinical presentation, and survival in patients with hepatocellular carcinoma. *PloS ONE*, 2013; 8:10: 1-8 e75982.
23. Quartuccio L, Maset M, **Soardo G**, Avellini C, De Vita Salvatore. Acetaminophen-induced liver injury in woman with febrile flare of Systemic lupus

erythematosus. Journal of Clinical Rheumatology • Volume 20, Number 6, September 2014.

24. Sechi LA, **Soardo G**, Catena C. Nonalcoholic fatty liver and left ventricular remodelling: now the prospective evidence. Journal of Hypertension May 2021
25. Meroni M, Longo M, Paolini E, Alisi A, Miele L, De Caro ER, Maggioni M, **Soardo G**, Valenti L, Fracanzani AL, Dongiovanni P. The rs599839A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients. Cancers 13(8): 1783 April 2021
26. Dongiovanni P, Meroni M, Petta S, Longo M, Alisi A, **Soardo G**, Valenti L, Miele L, Grimaudo S, Pennisi G, Grieco A, Consonni D, Fargion S, Fracanzani AL. Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochimica et Biophysica ACTA(BBA)-Molecular and Cell Biology of Lipids 1865(10): 158765 July 2020
27. Maier S, Donnini D, De Luca L, Avellini C, Sechi LA, **Soardo G**. Hepatocellular metastasis recurrence in liver transplant after treatment with direct antiviral agents. Clinical Journal Gastroenterology 2020; 13:260-266
28. GianLuca Colussi, Debora Donnini, Rosario F Brizzi, Silvia Maier, Luca Valenti, Cristiana Catena, Alessandro Cavarape, Leonardo A Sechi and **Giorgio Soardo** Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study World Journal Gastroenterology 2019; October 28; 25(40): 6094-6106
29. Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, **Soardo G**, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HE, Valenti L. Rare pathogenetic variants predispose to hepatocellular carcinoma in Non Alcoholic Fatty Liver Disease. Scientific Reports 2019; Mar 6;9(1):3682
30. Paola Dongiovanni, Marica Meroni, Rosellina M. Mancina, Guido Baselli, Raffaella Rametta, Serena Pelusi, Mcannisteo, Anna L. Fracanzani, Sara Badiali, Luca Miele, Stefania Grimaudo, Salvatore Petta, Elisabetta Bugianesi, **Giorgio Soardo**, Silvia Fargion, Jussi Pihlajamaki, Stefano Romeo, and Luca Valenti. Protein Phosphatase 1 Regulatory 3B Gene Variation Protects Against Hepatic Fat Accumulation and Fibrosis in Individuals at High Risk of Nonalcoholic Fatty Liver Disease. Hepatology Communication 2018 ;2:666-675
31. Bianco C, Jamialahmadi O, Pelusi S, Baselli G, Dongiovanni P, Zanoni I, Santoro L, Maier S, Liguori A, Meroni M, Borroni V, D'Ambrosio R, Spagnuolo R, Alisi A, Federico A, Bugianesi E, Petta S, Miele S, Vespasiani Gentilucci U, Anstee. Q, Stickel F, Hampe J, Fischer J, Berg T, Fracanzani AL, **Soardo G**, Reeves H, Prati D, Romeo S, Valenti L. Non-invasive stratification of hepatocellular carcinoma.

Risk in non-alcoholic fatty liver using polygenic risk scores. *Journal of Hepatology* 74(4). Nov 2020

32. Miriam Longo, Marica Meroni, Erika Paolini, Veronica Erconi, Fabrizia Carli, Francesco Fortunato, Dario Ronchi, Roberto Piciotti, Silvia Sbbatini, Chiara macchi, Anna Alisi, KLUca Miele, **Giorgio Soardo**, Giacomo Pietro comi, Luca Valenti, Massimiliano Ruscica, Anna Ludovica Fracanzani, Annalisa Gastaldelli, paola Dongiovanni. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in vitro models. *Cellular and Molecular gastroenterology and Hepatology* 2021
33. Serena Pelusi, Luisa Rnzoni, Francesco Malvestiti, Cristiana Bianco, Ilaria Marini, Roberta D'Ambrosio, Juri Alessandro Giannotta, **Giorgio Soardo**, Marco Maggioni, Daniele Prati, Luca Valenti. Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: a case series. *Liver International* 2022.
34. Sami Qadri, Noora Ahlholm, Ida Lønsmann, Paola Pellegrini, Anni Poikola, Panu k Luukkonen, Kimmo Porthan, Anne Juuti, Henna E Sammalkorpi, Anne K Penttilä, Roberta D'Ambrosio, **Giorgio Soardo**, Diana Julie Leeming, Morten Karsdal, Johanna Arola, Stergios Kechagias, Srena pelusi, Mattias Ekstedt, Luca valenti, Hannes Hagström, Hannele Yki.Järvinene Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease. *The Journal of Clinical Endocrinology and Metabolism* 2022.
35. Benedetta Donati, Alessandro Pietrelli, Piero Pingitore, Paola Dongiovanni, Andrea Caddeo, EPIDEMIC Study Group Investigators, Luca Miele, Salvatore Petta, Laura De Luca, **Giorgio Soardo**, Elisabetta Bugianesi, Renato Romagnoli, Quentin Anstee<sup>1</sup>, Helen Reeves, Anna Ludovica Fracanzani, Silvia Fargion, Stefano Romeo, Luca Valenti. Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. *Cancer Medicine* 2017 Aug;6(8):1930-1940
36. Benedetta Donati, Paola Dongiovanni, Stefano Romeo, Marica Meroni, Luca Miele, Salvatore Petta, Silvia Maier, Chiara Rosso, Laura De Luca, Ester Vanni, Stefania Grimaudo, Renato Romagnoli, Fabio Colli, Flaminia Ferri, Rosellina Margherita Mancina, Antonio Craxi, Anna Ludovica Fracanzani, Antonio Grieco, Stefano Ginanni Corradini, Alessio Aghemo, Massimo Colombo, **Giorgio Soardo**, Elisabetta Bugianesi, Silvia Fargion, and Luca Valenti. "The MBOAT7 rs641738 variant increases the risk of hepatocellular carcinoma in European individuals without cirrhosis". *Scientific Reports in Press*. 2017 Jul 3;7(1):4492.
37. Pablo J. Giraudi, Sabrina E. Gambaro, Sofia Ornelas Arroyo, Carla M. ChackeleVICIUS, Michela Giuricin, Marta Silvestri, Daniele Macor, Lory S. Crocé, Deborah Bonazza **Giorgio Soardo**, Nicolò de Manzini, Fabrizio Zanconati, Claudio Tiribelli, Silvia Palmisano, Natalia Rosso A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects. *Liver International*. 2017: 3;1-9

38. Dario Lorenzin, Riccardo Pravisani, Cosimo Alex Leo, Walter Bugiantella, **Giorgio Soardo**, Alessia Carnelutti, Baccarani Umberto and Andrea Risaliti. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization. *Cancer Biotherapy & Radiopharmaceuticals* 31(2):65-69 · March 2016
39. Righi E, Ivaldi F, Carnelutti A, Tomkova L, Villa G, Sartor A, **Soardo G**, Baccarani U, Pea F, Bassetti M. Immunologic and Pharmacologic Aspects in an Elderly Recipient of Liver Transplant With Pulmonary Aspergillosis and Multiple Comorbidities. *Exp Clin Transplant*. 2016 Oct;14(5):567-570
40. Federico Pea, Elda Righi, Piergiorgio Cojutti, Alessia Carnelutti, Umberto Baccarani, **Giorgio Soardo** and Matteo Bassetti. Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis. *J Antimicrob Chemother* 2014
41. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. *Hepatology*. 2011 2;54(3):868-78
42. Comuzzi C, Lorenzin D, Rossetto A, Faraci MG, Nicolini D, Garelli P, Bresadola V, Toniutto P, **Soardo G**, Baroni GS, Adani GL, Risaliti A, Baccarani U Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients. *Transplantation Proceedings*, (2010) 42, 1320–1321.
43. Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, **Soardo G**, Di Piazza L, Bernardi S, Bertolotto M, Pinamonti B, Fabris B, Sechi LA Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. *Nutr Metab& Cardiovascular Disease*. 2009;19, 646-653
44. Uzzau A, Rossetto A, Carrer F, Elezi B, Pontello D, Baruchello V, Piccoli E, Molaro R, Benzone E, **Soardo G**, De Anna D, Hepatocellular carcinoma in the elderly. *BMC Geriatrics*. 2009 9 (suppl. 1) : A 59
45. Floreani A, Carderi I, Parenoster D, **Soardo G**, Azzaroli F, Esposito W, Montagnani M, Marchesoni D, Variola A, Rosa Rizzotto E, Braghin C, Gazzella G Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. *Dig Liv Dis* 2008 May 40(5); 366-370.

46. Fallo F, Dalla Pozza A, Sonino N, Federspil Gi, Ermani M, Baroselli S, Catena Cr, **Soardo G**, Carretta R, Belgrado D, Fabris B, Sechi LA Non-alcoholic fatty liver disease, adiponectin and insulin resistance in dipper and non-dipper essential hypertensive patients. J Hypertension 2008
47. Floreani A, Carderi I, Parenoster D, **Soardo G**, Azzaroli F, Esposito W, Variola A, Tommasi AM, Marchesoni D, Braghin C, Gazzella G Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther. 2006; 23: 1649-1653.
48. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S HCC-NAFLD Italian Study Group (**SoardoG**). Clinical patterns of hepatocellular carcinoma in Non Alcoholic Fatty Liver Disease: a multicenter prospective study. Hepatology 2016 Mar;63(3):827-38
49. Catena C, Lapenna R, Baroselli S, Novello M, Nadalini E, Colussi GL, **Soardo G**, Cavarape A, Sechi LA The emergent cardiovascular risk factors and organ damage in arterial hypertension. Current Hypertension Reviews. 2005; 1; 189-200.
50. Catena C, Novello M, La Penna R, Caroselli S, Colussi G., Nadalini E, Favret G, Cavarape A, **Soardo G**, Sechi LA New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoproteins. J Hypertension 2005; 23: 1617-1631.
51. Adani GL, Baccarani U, Risaliti A, Sainz-Barriga M, Lorenzin D, Costa G, Toniutto P, **Soardo G**, Montanaro D, Viale P, Della Rocca G, Bresadola F A single-center experience of late retransplantation of the liver. Transplant Proc 2005 Jul-Aug;37(6):2599-600.
52. Fabris C, Pirisi M, Panozzo MP, **Soardo G**, Toniutto P, Hocza V, Bartoli E. Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease. J Clin Pathol 1993; 46:364-7.
53. Pirisi M, Fabris C, Panozzo MP, **Soardo G**, Toniutto P, Bartoli E. Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression of the acute phase response. Dis Markers 1993; 11:103-11.
54. Pirisi M, Fabris C, Falleti E, **Soardo G**, Toniutto P, Gonano F, Bartoli E. Evidence for a multifactorial control of serum erythropoietin concentration in liver disease. Clin Chim Acta 1993; 219:47-55.
55. Falleti E, Pirisi M, Fabris C, Bortolotti N, **Soardo G**, Toniutto P, Gonano F, Bartoli E. Increase of serum  $\alpha$ 1-acid glycoprotein despite the decline of liver synthetic function in cirrhotics with hepatocellular carcinoma. Eur J Chem Clin Biochem 1993; 31:407-11.
56. Fabris C, Pirisi M, **Soardo G**, Falleti E, Pezzetta F, Vitulli D, Toniutto P, Bortolotti N, Gonano F, Bartoli E. Value of serum C-reactive protein measurement

in the detection of hepatocellular carcinoma superimposed on liver cirrhosis. *J Cancer Res Clin Oncol* 1994; 120:229-232.

57. Pirisi M, Fabris C, **Soardo G**, Cecchin E., Toniutto P., Bartoli E.: . Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. *J Hepatol* 1994; 21:376-380.
58. Pirisi M, Fabris C, Toniutto P, Falletti E, Tisminentzky S, Gerotto M, **Soardo G**, Vitulli D, Del Forno M, Baralle F, Bartoli E : Endogenous interferon- $\alpha$  concentration and outcome of interferon treatment in patients with chronic hepatitis C. *Diseases and Science*, 42,4 (1997) 767-771
59. Pirisi M, Fabris C, **Soardo G**, Falletti E, Gasparini D, Vitulli D, Toniutto P, Gonano F, Bartoli E Hepatic release of erythropoietin induced by transarterial chemoembolization in patients with hepatocellular carcinoma. *Hepatology* 1995, 22:148-152.
60. Fabris C, Pirisi M, **Soardo G**, Panozzo M.P, Vitulli D, Toniutto P, Bartoli E Prediction of jaundice by markers of inflammation in patients with liver disease. *Med Sci Res* 1995; 23:353-4.
61. Fabris C, Falletti E, Pirisi M, **Soardo G**, Toniutto P, Vitulli D, Bortolotti N, Gonano F, Bartoli E. Aspecific increase of serum carbohydrate antigen 19-9 in patients with liver disease is predicted by circulating levels of adhesion molecules. *Clin Chim Acta* 1995, 243:25-33.
62. Pirisi M, Fabris C, Ceriello A, **Soardo G**, Giacomello R Toniutto P, Vitulli D, Gonano F, Bartoli E et al Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: evidence against a cause-effect relationship. *Acta Gastroenterol Belgica* 58: 230-237: 1995
63. Pirisi M, Fabris C, **Soardo G**, Toniutto P, Vitulli D, Bartoli E. Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma. *Eur J Cancer* 1996, 32A:221-225.
64. Fabris C, Pirisi M, **Soardo G**, Toniutto P, Falletti E, Vitulli D, Pezzetta F, Gonano F, Bartoli E. Diagnostic usefulness of acute phase protein measurement in hepatocellular carcinoma. *Cancer Invest* 1996, 14:103-108.
65. Falletti E, Fabris C, Pirisi M, **Soardo G**, Vitulli D, Toniutto P, Bortolotti N, Gonano F, Bartoli E. Circulating intercellular adhesion molecule-1 predicts aspecific elevation of alpha-1-fetoprotein. *J Cancer Res Clin Oncol* 1996, 122:366-9.
66. Pirisi M, Fabris C, Falletti E, **Soardo G**, Toniutto P, Vitulli D, Gonano F, Bartoli E Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases. *Dis Markers* 1996, 13:11-17.

67. Pirisi M, Vitulli D, Falleti E, Fabris C, Soardo G, Del Forno M, Bardus P, Gonano F, Bartoli E. Increased soluble ICAM-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease. *J Clin Pathol* 1997, 50:50-53.
68. Pirisi M, Fabris C, Toniutto P, Falleti E, Tisminetzky SG, Gerotto M, Soardo G, Vitulli D, Del Forno M, Baralle F, Bartoli E. Endogenous interferon alpha and outcome of interferon treatment in patients with chronic hepatitis C. *Digest Dis Sci* 1997; 42:767-771.
69. Falleti E, Pirisi M, Fabris C, Bortolotti N, Soardo G, Gonano F, Bartoli E. Circulating standard CD44 isoform in patients with liver disease: relationship with other soluble adhesion molecules and evaluation of diagnostic usefulness. *Clin Biochem* 1997, 30:69-73.
70. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. *Clin Chim Acta* 1997, 261:159-165.
71. Pirisi M, Fabris C, Soardo G, Bartoli E. Activation of the endogenous interferon system, expression of interferon alpha receptors, and response to interferon therapy in chronic hepatitis C. *J Hepatol*, 26 (1997) Oct 27(4): 768-9
72. Toniutto P, Pirisi M, Fabris C, Bardus P, Soardo G, Vitulli D, Tisminetzky SG, Pacco P, Gasparini V, Baralle F, Bartoli E. High prevalence of infection by hepatitis G virus in patients with hepatic and extrahepatic malignancies. *J Hepatol*, 1998;28:550-555
73. Fabris C, Panozzo MP, Pirisi M, Soardo G, Bartoli E. Liberazione di radicali ossigeno ed intensità del processo infiammatorio in corso di epatopatie. *Atti 5° Settimana Italiana della Malattie Digestive (SIMAD)*, Bologna, 1992. Vol 2, pp 603-606.
74. Pirisi M, Cecchin E, Fabris C, Soardo G, Bartoli E. L'eritropoietina può correggere la piastrinopenia della cirrosi epatica. *Atti 5° Settimana Italiana della Malattie Digestive (SIMAD)*, Bologna, 1992. Vol 2, pp 677-680.
75. Vitulli D, Pezzetta F, Toniutto P, Fabris C, Pirisi M, Soardo G, Falleti E, Bortolotti N, Gonano F, Bartoli E. Accuratezza della prolil-idrossilasi sierica nel predire il consumo di alcool nei pazienti con epatopatia. In: Carrieri F, Albano O, Marzi V. *L'Alcoologia verso il 2000: progressi e formazione*. Roma, CIC Edizioni Internazionali, pp 401-403, 1993.
76. Pirisi M, Fabris C, Soardo G, Vitulli D, Pezzetta F, Toniutto P, De Martinis M, Bartoli E. Clinical, biohumoral and histologic aspects of liver disease related to chronic hepatitis C virus (HCV) infection. *Il Friuli Medico - Alpe Adria Journal of Medicine* 49:613-22, 1994.



77. Cattin L, Da Col PG, Fonda M, Mameli MG, Soardo G, Feruglio FS. L'iperalfalipoproteinemia familiare. Descrizione di una famiglia. Familial hyperalphalipoproteinemia . A family study. Atti congresso Alpe Adria Aterosclerosis.Giornale dell'Aterosclerosi,suppl.2,105-113. 1983
78. Andreoli P, Brosolo P, Macor C, Rossitti P, Zilli M, Da Broi GL, Buda F, Tubaro G, Plaino R, Buda C, Soardo G, Aragona P. Screening per lesioni pre cancerose e cancerose del grosso intestino mediante test al guaiaco su popolazione asintomatica.Convivia Medica. 3 ;1-13: 1985.
79. Aragona P, Buda F, Buda C, Brosolo P, Filiputti R, Plaino R, Samani F, Santarossa M, Soardo G, Tubaro G, Orlando-Zon L. Valutazione dell'incidenza della cancro-cirrosi nella cirrosi senile. Studio retrospettivo su 1253 autopsie. Clinica Europea. fascicolo5: 1-11: 1985.
80. Buda F, Sisto R, Filiputti R, De Zerbi G, Di Nardo G, Soardo G, Plaino R, Aragona P, Giani G, Binotto F, Gentile G, Papadia A, Pighin A, Buda C, La torre F. Effetti della Timopentina 23-36 su alcune popolazioni T-Linfocitarie(OKT3, OKT4, OKT8, OKT4/OKT8) di donne con neoplasia mammaria N+ localmente avanzata . Acta oncologica Vol IX; 4; 381-387; 1988.

#### **Elenco Pubblicazioni Abstract**

81. Soardo G, Toniutto P, Vitulli D, Fabris C, Pirisi M. I test di funzionalità epatica: guida ad una corretta utilizzazione. Notiziario dell'Università degli studi di Udine. Bollettino della Facoltà di Medicina e Chirurgia N.1, Suppl. al N. 4, 1994.
82. Soardo G, Pirisi M, Fabris C, Falletti E, Gasparini D, Vitulli D, Toniutto P, Gonano F, Bartoli E. Evidenza di un rilascio epatico di eritropoietina dopo chemioembolizzazione per carcinoma epatocellulare. Atti del Congresso Nazionale delle malattie digestive, Firenze 3-7 Dicembre, 1994, Scientific Press, pp. 767-9.
83. Fabris C, Pirisi M, Falletti E, Soardo G, Vitulli D, Toniutto P, Bortolotti N, Gonano F, Bartoli E. I livelli sierici della molecola di adesione intercellulare-1 predicono le elevazioni aspecifiche di alfa-fetoproteina. Atti del Congresso Nazionale delle malattie digestive, Firenze 3-7 Dicembre, 1994, Scientific Press, pp. 311-4.
84. Soardo G, Pirisi M, Gasparini D, Del Forno M, Bardus P, Fabris C, Toniutto P, Vitulli D, Bartoli E. Complicanze della terapia chemioembolizzante in pazienti con epatocarcinoma. Atti del XV Congresso Internazionale C.O.S.M.A.D., Giornate Gastroenterologiche Italo-Spagnole, Capri 31 maggio - 3 giugno 1995. Casa Editrice L'Antologia, Napoli.
85. Soardo G, Pirisi M, Maurizio R, Bartoli E. Problemi internistici in corso di malattia di Alzheimer. Atti del I Corso di Formazione sulla malattia di Alzheimer, Fondazione Morpurgo - Hoffman, Udine, 1996.

86. Pirisi M, Soardo G, Del Forno M., Bardus P., Bartoli E. :Infezioni nel paziente con malattia di Alzheimer. Atti del I Corso di Formazione sulla malattia di Alzheimer, Fondazione Morpurgo - Hoffman, Udine, 1996.
87. Soardo G, Pirisi M, Fabris C, Hocza V, Toniutto P, Bartoli E. Raised serum alpha-1-antitrypsin levels in primary hepatocellular carcinoma. Hepato-Gastroenterology 1992; 39:26.
88. Soardo G, Pirisi M, Fonda M, Fabris C, Cattin L, Feruglio FS. Increased incidence of cholelithiasis in familial hyperalphalipoproteinemia. Lipids in Medicine '92, Italy-USA conference. Bologna, Italy, May 10-12, 1992.
89. Toniutto P, Fabris C, Pirisi M, Soardo G, Hocza V, Bartoli E. Detection of raised serum alpha-1-antitrypsin levels in primary liver cancer. 3<sup>rd</sup> International Gastro-Surgical Club (IGSC) Joint Meeting of Surgeons and Gastroenterologists. Padua, Italy, June 24-27, 1992
90. Soardo G, Pirisi M., Fabris C, Toniutto P, Hocza V, Bartoli E. Raised serum levels of alpha-1-antitrypsin in primary hepatocellular carcinoma. Ital J Gastroenterol 1992; 24:305-6.
91. Pirisi M, Fabris C, Falletti E, Soardo G, Toniutto P, Hocza V, Gonano F, Bartoli E. Elevation of serum erythropoietin levels in liver disease: role of declining liver function. 2<sup>nd</sup> Alpe-Adria Congress on Clinical Chemistry and Laboratory Medicine. Graz, Austria, 12-14 November 1992.
92. Hocza V, Pirisi M, Fabris C, Panozzo MP, Soardo G, Toniutto P, Bartoli E. Serum phospholipase A2 activity in chronic liver disease and primary liver cancer as part of the acute phase response. 2<sup>nd</sup> Alpe-Adria Congress on Clinical Chemistry and Laboratory Medicine. Graz, Austria, 12-14 November 1992.
93. Soardo G, Pirisi M, Fabris C, Panozzo MP, Toniutto P, Hocza V, Bartoli E. Raised serum lipid peroxides levels in acute and chronic liver disease: relationship to the intensity of inflammatory damage. 2<sup>nd</sup> Alpe-Adria Congress on Clinical Chemistry and Laboratory Medicine. Graz, Austria, 12-14 November 1992.
94. Pirisi M, Fabris C, Falletti E, Soardo G, Toniutto P, Hocza V, Gonano F, Bartoli E. Raised serum erythropoietin (EPO) levels in liver diseases: influence of declining liver function. J Hepatol 1992; 16:S33.
95. Pirisi M, Ferroni P., Fabris C., Vitulli D., Pezzetta F, Soardo G., Toniutto P., Gasparini V., Bartoli E.: Detection of antibodies to epitopes in hepatitis C virus (HCV) core protein in patients with chronic liver disease. Biology, immunopathology and clinic of hepatitis viruses, Parma, 3-5 giugno 1993. Abstract
96. De Paoli P, Caffau C, D'Andrea M, Pirisi M, Fabris C, Soardo G, Bartoli E, Santini G. Serum levels of TNF alfa, IL1 beta and IL6 in liver diseases. 2<sup>nd</sup>

International Congress on Cytokines: basic principles and clinical applications.  
Florence, Italy, March 23-25, 1992.

97. Pirisi M, Cecchin E, Fabris C, Soardo G, Bartoli E. L'eritropoietina può correggere la piastrinopenia in corso di cirrosi epatica. 5<sup>a</sup> Settimana Italiana delle malattie digestive. Bologna, Italia, 31 Maggio - 4 Giugno 1992. Riassunti, p.102.
98. Fabris C, Panozzo MP, Pirisi M, Soardo G, Bartoli E. Liberazione di radicali ossigeno ed intensità del processo infiammatorio in corso di epatopatie. Bologna, Italia, 31 Maggio - 4 Giugno 1992. Riassunti, p.50.
99. Toniutto P, Pirisi M, Fabris C, Ceriello A, Soardo G, Giacomello R, Gonano F, Bartoli E. Aumento relativo dell'attività trombinica ed aumentata fibrinolisi in presenza di severa diminuzione della sintesi epatica. Atti del II Convegno Triveneto "Attualità e prospettive in Epatologia", Padova, 6 Novembre 1992.
100. Falletti E, Bortolotti N, Pirisi M, Soardo G, et al. The decline of liver function contrasts raise of serum orosomucoid (AGP) in hepatocellular carcinoma (HCC). Ann Biol Clin, 51:507, 1993.
101. Falletti E, Bortolotti N, Pirisi M, Fabris C, Soardo G, et al. Increased serum erythropoietin (EPO) levels in liver diseases and relationship to liver function. Ann Biol Clin 51:412, 1993.
102. Soardo G, Pirisi M, Ferraccioli GF, Avellini C., Scott C., Fabris C., Toniutto P., Pezzetta F., Vitulli D., Beltrami A.C., Bartoli E.: Sialoadenitis associated with HCV-related chronic liver disease differs from Sjogren Syndrome. Biology, Immunopathology and clinic of hepatitis viruses, Parma, 1993.
103. Soardo G, Pirisi M, Fonda M., Toniutto P., Vitulli D., Pezzetta F., Fabris C., Cattin L., Bartoli E.: Effect of interferon alpha therapy on lipid metabolism in patients with chronic viral liver disease. Biology, Immunopathology and clinic of hepatitis viruses, Parma, 1993..
104. Toniutto P, Vitulli D, Pezzetta F, Soardo G, Falletti E, Pirisi M et al. Serum procollagen I, collagen IV and prolyl-hydroxylase in liver disease. Fat Storing Cells and Liver Fibrosis, Florence, 1993.
105. Pirisi M, Brosolo P, Fabris C, Soardo G, et al. Correction of thrombocytopenia of chronic liver disease by erythropoietin treatment. II United Gastroenterology Week, Barcelona, 1993.
106. Soardo G, Brosolo P, Fabris C, Pirisi M et al. Hyperfibrinolysis and "relative" increase in thrombin activity in liver disease. II United Gastroenterology Week, Barcelona, 1993.

107. Brosolo P, Soardo G, Pirisi M et al. Raise of serum  $\alpha$ 1-acid glycoprotein in liver cancer contrasted by the decline of liver function. II United Gastroenterology Week, Barcelona, 1993.
108. Fabris C, Pirisi M, Soardo G, et al. Prognostic value of serum alpha-1-antitrypsin concentration in hepatocellular carcinoma. J Hepatol 18(Suppl. 1):S116, 1993.
109. Soardo G, Pirisi M, Fonda M, et al. Effect of treatment with interferon alpha on lipid metabolism in chronic viral liver disease. J Hepatol 18(Suppl. 1):S172, 1993.
110. Soardo G, Toniutto P, Fabris C, Pirisi M, Panozzo MP, Vitulli D, Pezzetta F, Bartoli E. Ruolo dei mediatori della flogosi nel determinare iperbilirubinemia in corso di epatopatia. XCIV Congresso Nazionale della Società Italiana di Medicina Interna, Roma 14-18 Ottobre 1993.
111. Vitulli D, Pezzetta F, Pirisi M, Fabris C, Soardo G, et al. Riscontro di anticorpi contro epitopi della proteina del core del virus C dell'epatite (HCV) in pazienti con epatopatia cronica. XCIV Congresso Nazionale della Società Italiana di Medicina Interna, Roma 14-18 Ottobre 1993.
112. Toniutto P, Vitulli D, Pezzetta F, Fabris C, Pirisi M, Soardo G, et al. Prolidrossilasi sierica: un accurato marker del consumo di alcool nei pazienti con epatopatia. III Convegno "Attualità e prospettive in Epatologia", Padova, 26 Ottobre 1993.
113. Toniutto P, Vitulli D, Fabris C, Pirisi M, Falleti E, Soardo G, et al. Caratterizzazione della risposta anticorpale contro la proteina del core del virus C dell'epatite (HCV). III Convegno "Attualità e prospettive in Epatologia", Padova, 26 Ottobre 1993.
114. Gonano F, Pirisi M, Soardo G, Fonda M, Fabris C, Falleti E, Bartoli E. Changes in lipid metabolism by treatment with interferon alpha in patients with chronic viral liver disease. Clin Biochem Revs 14:225, 1993.
115. Gonano F, Pirisi M, Fabris C, Falleti E, Soardo G, Bartoli E. Multifactorial control of serum erythropoietin levels in liver disease. Clin Biochem Revs 14:348, 1993.
116. Fabris C, Pirisi M, Vitulli D, Pezzetta F, Soardo G, Toniutto P, Bartoli E. Prognostic value of serum alpha-1-antitrypsin concentration in hepatocellular carcinoma. Ital J Gastroenterol 25(Suppl. 1):74, 1993.
117. Csillaghy A, Vitulli D, Pezzetta F, Fabris C, Soardo G, Toniutto P, Pirisi M, Bartoli E. Prognostic value of serum alpha-1-antitrypsin concentration in hepatocellular carcinoma. Update on hepatology and gastroenterology: from basic science to clinical medicine. Parma, Italy, September 30 - October 2, 1993.
118. Pirisi M, Fabris C, Soardo G, et al. Evidence for Hepatic release of erythropoietin after chemoembolization for hepatocellular carcinoma. J. Hepatol 21(1994)s 85.

119. Pirisi M, Toniutto P, Fabris C, Soardo G, et al. Significance of anti-envelope antibodies in anti-HCV positive patients with and without liver disease. J Hepatol 21,suppl 1,( 1994) S61,
120. Soardo G, Pirisi M, Fabris C, Falleti E, Gasparini D, Vitulli, D, Toniutto P, Gonano F, Bartoli E. Evidence for hepatic release of erythropoietin after chemoembolization for hepatocellular carcinoma. Ital J Gastroenterol 1994; 26:149.
121. Fabris C, Pirisi M, Falleti E, Soardo G, Vitulli, D, Toniutto P, Bortolotti N, Gonano F, Bartoli E. Circulating intercellular adhesion molecule-1 predicts aspecific elevation of alpha-1-fetoprotein. Ital J Gastroenterol 1994; 26:63..
122. Soardo G,Pirisi M., Gasparini D.,Del Forno M., Bardus P., Fabris C., Toniutto P., Vitulli D., Bartolo E.:Complicanze dopo chemioembolizzazione transarteriosa per epatocarcinoma: incidenza e fattori predittivi. XCVI Congresso Nazionale della Società Italiana di Medicina Interna; Roma 12-15 ottobre 1995. Volume degli Abstracts, p.138
123. Soardo G., Pirisi M., Gasparini D., Del forno M.,Fabris C.,Bardus P., Toniutto P., Vitulli D., Bartoli E.: Fattori predittivi di comparsa di complicanze severe dopo chemioembolizzazione transarteriosa per epatocarcinoma. *Simposio Internazionale La Terapia delle Malattie Epatiche 1995, Milano 2-4 Ottobre 1995*
124. Vitulli D, Soardo G, Fabris C, Falleti E, Bortolotti N, Federico E, Toniutto P, Capraro R, Pirisi M, Trina M, Gonano F, Bartoli E. A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis. Il Friuli Medico-Alpe Adria Journal of Medicine 1996, Suppl.1:107.
125. Soardo G, Fabris C, Federico E, Toniutto P, Bardus P, Del Forno M, Capraro R, Pirisi M, Bartoli E. Serum LDL-cholesterol concentration and viral etiology B or C in patients with chronic hepatitis. Il Friuli Medico-Alpe Adria Journal of Medicine 1996, Suppl.1:101.
126. Toniutto P, Soardo G, Fabris C, Falleti E, Trina M, Vitulli D, Bortolotti N, Bardus P, Federico E, Del Forno M, Pirisi M, Gonano F, Bartoli E. Diagnostic usefulness of the measurement of soluble standard CD44 in patients with liver disease. Il Friuli Medico-Alpe Adria Journal of Medicine 1996, Suppl.1:104.
127. Del Forno M, Federico E, Soardo G, Vitulli D, Fabris C, Toniutto P; Bardus P, Pirisi M, Bartoli E. Etiologic agents of chronic viral hepatitis and serum LDL-cholesterol concentration. 4<sup>th</sup> Postgraduate Course in Hepatology, Ljubljana, 1996.
128. Federico E, Del Forno M, Falleti E, Soardo G, Toniutto P; Vitulli D, Bardus P, Fabris C, Pirisi M, Bartoli E. Comparison of procollagen I, procollagen III, collagen IV, and prolyl hydroxylase in the diagnosis of cirrhosis. 4<sup>th</sup> Postgraduate Course in Hepatology, Ljubljana, 1996.

129. Bortolotti N, Falleti E, Pirisi M, Fabris C, Soardo G, Bardus P, Gonano F. Diagnostic usefulness of the measurement of soluble standard CD44 in patients with liver disease. Proceedings of the XVI International Congress of Clinical Chemistry, London July 8-12, 1996.
130. Fabris C, Federico E, Bortolotti N, Falleti E, Soardo G, Ceriello A, Pirisi M. Changes in plasma antioxidant activity following a standard meal in patients with cirrhosis. *Hepatology* 24 (1996) 449.
131. Bardus P, Toniutto P, Pirisi M, Ferroni P, Gasparini V, Tisminetzky S, Fabris C, Soardo G, Pacco P, Baralle F, Bartoli E. Exposure to hepatitis G virus infection in Italian patients with hepatocellular carcinoma. *Cancer Detect Prev* 1996, 20:416.
132. Vitulli D, Pirisi M, Falleti E, Fabris C, Soardo G, Del Forno M, Bardus P, Gonano F, Bartoli E. Increased soluble ICAM-1 levels and impaired delayed-type hypersensitivity skin tests in liver diseases. *Hepatology* 24 (1996) 1873
133. Federico E, Soardo G, Fabris C, Bortolotti N, Falleti E, Ceriello A, Pirisi M, Gonano F, Bartoli E. Changes in plasma antioxidant activity following a standard meal in patients with cirrhosis. *It J Gastroenterol* 1996, 28:239.
134. Toniutto P, Soardo G, Pirisi M, Ferroni P, Gasparini V, Tisminetzky SG, Fabris C, Pacco P, Brusaferrero S, Baralle F, Bartoli E. Detection of hepatitis G virus infection by enzyme immunoassay and polymerase chain reaction. *It J Gastroenterol*, 28:229.
135. Toniutto P, Pirisi M, Fabris C, Soardo G, Bardus P, Scott C, Avellini C, Beltrami CA, Bartoli E. Portal vein thrombosis: prevalence and impact on survival of patients with hepatocellular carcinoma. *Hepatocellular carcinoma at the sunrise of the year 2000*, Venice 23-25, 1997.
136. Toniutto P, Pirisi M, Fabris C, Soardo G, Bardus P, Pacco P, Vitulli E, Bartoli E. High prevalence of hepatitis G virus infection in patients with hepatocellular carcinoma. *Hepatocellular carcinoma at the sunrise of the year 2000*, Venice 23-25, 1997.
137. Fabris C, Pirisi M, Scott C, Avellini C, Soardo G, Federico E, Vitulli D, Falleti E, Beltrami CA, Bartoli E. Zonal distribution of stainable iron and activity index in chronic hepatitis C. *J Hepatol*, suppl.1,26,(1997).
138. Toniutto P, Pirisi M, Fabris C, Soardo G, Bardus P, Pacco P, Del Forno M, Bartoli E. High prevalence of hepatitis G virus infection in patients with hepatocellular carcinoma. *J Hepatol*, suppl .1,26 (1997)141.
139. Falleti E, Bortolotti N, Fabris C, Federico E, Soardo G, Pirisi M, Bartoli E, Gonano F. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. *Adv Clin Pathol* 1997, 2(Suppl. 1):38..

140. Pirisi M, Toniutto P, Fabris C, Soardo G, Bardus P, Vitulli D, Del Forno M, Federico E, Mattiuzzo M, Maurizio R, Bartoli E. High prevalence of hepatitis G virus infection in patients with hepatic or extrahepatic malignancies. *Hepatology*, 26,4 (1997) n°1816.
141. Toniutto P, Pirisi M, Fabris C, Soardo G, Pacco P, Galai T, Liani D, Del Forno M, Gasparini V, Bartoli E. Immunoreactivity to synthetic peptides derived from the hepatitis G virus polyprotein in viremic and nonviremic patients. *Hepatology*, 26,4,(1997)n°779
142. Toniutto P, Pirisi M, Fabris C, Soardo G, Vitulli D, Federico E, Del Forno M, Mattiuzzo M, Maurizio R, Pacco P, Gasparini V, Bartoli E. Immunoreactivity to putative B-cell epitopes of hepatitis G virus polyprotein in viremic and nonviremic patients. *It J Gastroenterol Hepatol* 1997, 29 (Suppl 1):A32.
143. Soardo G, Federico E, Fabris C, Pirisi M, Bortolotti N, Falleti E, Del Forno M, Mattiuzzo M, Maurizio R, Gonano F, Bartoli E. Oxidative stress and increased plasma iron concentration following a standard meal: a study in patients with cirrhosis. 2<sup>nd</sup> Mitteleurope-Countries Meeting of Internal Medicine, Olomouc (Czech Republic), September 18-20, 1997.
144. Soardo G, Fabris C, Pirisi M, Federico E, Falleti E, Vitulli D, Del Forno M, Mattiuzzo M, Maurizio R, Toniutto P, Bortolotti N, Gonano F, Bartoli E. Association between release of tumor necrosis factor and response to interferon therapy in chronic hepatitis C. 2<sup>nd</sup> Mitteleurope-Countries Meeting of Internal Medicine, Olomouc (Czech Republic), September 18-20, 1997.
145. Soardo G, Fabris C, Pirisi M, Scott C, Bardus P, Avellini C, Vitulli D, Federico E, Del Forno M, Mattiuzzo M, Maurizio R, Beltrami CA, Bartoli E. Portal vein thrombosis: prevalence and impact on survival of patients with hepatocellular carcinoma. 2<sup>nd</sup> Mitteleurope-Countries Meeting of Internal Medicine, Olomouc (Czech Republic), September 18-20, 1997.
146. Toniutto P, Soardo G, Pirisi M, Fabris C, Bardus P, Vitulli D, Del Forno M, Federico E, Mattiuzzo M, Maurizio R, Bartoli E. High prevalence of hepatitis G virus infection in patients with hepatic and extrahepatic malignancies. 2<sup>nd</sup> Mitteleurope-Countries Meeting of Internal Medicine, Olomouc (Czech Republic), September 18-20, 1997.
147. Toniutto P, Soardo G, Pirisi M, Fabris C, Lombardelli T, Falleti E, Vitulli D, Del Forno M, Mattiuzzo M, Maurizio R, Gasparini V, Bartoli E. Factors associated with persistent hepatitis G virus and hepatitis C virus infection in intravenous drug users. 2<sup>nd</sup> Mitteleurope-Countries Meeting of Internal Medicine, Olomouc (Czech Republic), September 18-20, 1997.
148. Toniutto P, Soardo G, Pirisi M, Fabris C, Vitulli D, Federico E, Del Forno M, Mattiuzzo M, Maurizio R, Pacco P, Gasparini V, Bartoli E. Immunoreactivity to

putative B-cell epitopes of hepatitis G virus polyprotein in viremic and nonviremic patients. 2<sup>nd</sup> Mitteleurope-Countries Meeting of Internal Medicine, Olomouc (Czech Republic), September 18-20, 1997.

149. Risaliti A, Corno V, Marcon G Pirisi M. Soardo G., Bulligan mg., Del Forno M., Donini A., Bresadola F.: cyclosporine associated acute cerebellar syndrome after liver transplantation J. Hepatol, 28, suppl 1 (1998) c01/031.
150. Pirisi M, Federico E, Fabris C, Bortolotti N, Falleti E, Soardo G., Mattiuzzo M, Gonano F, Bartoli E. Effect of eating on total plasma radical-trapping antioxidant activity in patients with cirrhosis. J Hepatol, suppl. 1, 8(1998), 219.
151. Fabris C., Pirisi M., Falleti E., Soardo G., Gonano F., Bartoli E.: Prediction of serum markers of fibrosis by levels of circulating intracellular Adhesion Molecule 1 in acute and chronic liver disease. Clin .Biochem. 27;5 (1994), 407-412
152. Pirisi M., Falleti E., Fabris C., Soardo G., Toniutto P., Vitulli D., Pezzetta F., Bortolotti N., Gonano F., Bartoli E.: Circulating intracellular Adhesion Molecule A1(c-ICAM-1) concentration in liver disease: relationship with cholestasis and functioning hepatic mass. Am. J. Clin. Patol. 102, 5(1994) 600-604.
153. Pirisi M., Scott C., Ferraccioli G., Soardo G., Zilli R., Toniutto P., Avellini C., Vitulli D., Miotti A.M., Beltrami C.A., Bartoli E.: Mild sialoadenitis: a common finding in patients with hepatitis C virus infection. Scand. J. Gastroenterol. 29 (1994) 940-42.
154. Pirisi M., Fabris C., Falleti F., Soardo G., Toniutto P., Gonano F., Bartoli E.: Evidence for a multifactorial control of serum erythropoietin concentration in liver disease. Clin. Chim. Acta, 219 (1993) 47-55.
155. Fabris C., Pirisi M., Soardo G., Falleti E., Pezzetta F., Vitulli D., Toniutto P., Bortolotti N., Gonano F., Bartoli E.: Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis. J. Clin. Res. Clin. Oncol. (1994) 120:229-232.
156. Pirisi M., Soardo G., Fabris C., Vitulli D., Toniutto P., Bartoli E.: Blood lipids and prediction of response to interferon therapy in hepatitis C. II International Symposium on lymphoblastoid alfa-interferon 22-24 october 1994 Barcelona, Spain poster n°72. Selezionato come miglior poster.
157. Cattin L., DaCol P.G., Fonda M., Mameli M.G., Soardo G., Feruglio F.S.: L'iperalfalipoproteinemia familiare: descrizione di una famiglia. Giornale dell'aterosclerosi, suppl. 2, 1983, 105-113.
158. Feruglio F.S., Cattin L., DaCol P.G., Fonda M., Mameli M.G., Soardo G.: The hyperalphalipoproteinemia. II Incontro Italo-Asustriaco sull'Aterosclerosi Trieste 2-3 maggio 1983.



159. Falletti E., Soardo G.,Ceriello A.,De Stasio G.,Bortolotti N.,Gonano F.:Valutazione di alcuni parametri dello stato lipidico e coagulativo in una famiglia iperalfalipoproteinemica.SiBioC 92, Bari 7-10 ottobre 1992
160. Ceriello A.,Giacomello R .,Colauro A.,De Stasio G.,Mozz E.,Menegon M.G.,Soardo G.,Toniutto P.,Gonano F.:Iperfibrinogenemia quale marker di attivazione trombinica.12° Congresso Nazionale Società Italiana Studio Emostasi e Trombosi,Parma 27 settembre-1 ottobre 1992.
161. Falletti E., Bortolotti N., Pirisi M., Soardo G.,Gasparini D.,D'Agosto A.,Vitulli D.,Toniutto P.,Gonano F.,Bartoli E.:Hepatic liberation of heritropoietin after transarterial chemoembolization for hepatocellular carcinoma.SiBioC 94,Firenze 2 ottobre 1994,Montecatini 3-4 ottobre 1994.
162. Falletti E., Bortolotti N., Fabris C., Toniutto P., Pirisi M.,Vitulli D., Soardo G., D'Agosto A., Gonano F., Feroni P., Gasparini V., Bartoli E.:Serum immunoreactivity to synthetic peptides derived from hepatitis C virus (HCV)core protein in patients with neoplastic and no-neoplastic HCV-related liver disease.SiBioC 94,Firenze 2 ottobre,Montecatini 3-4 ottobre 1994.
163. Toniutto P., Soardo G., Pirisi M.,Falletti E.,Gasparini D.,Vitulli D.,Gonano F.,Bartoli E.:Evidenza di un rilascio epatico di eritropoietina dopo chemioembolizzazione per carcinoma epatocellulare Atti del 4° Convegno "Attualità e prospettive in Epatologia:Padova,28 ottobre 1994.
164. Falletti E., Fabris C., Cavarape A., Pirisi M., Soardo G.,Toniutto P.,Vitulli D., Bortolotti N., Gonano F., Bartoli E: Spurious elevation of CA19 –9 in livr disease is predicted by circulating Adhesive Molecule A-1.Digestion 55,5,(1994) 296.Abstract from XXVI Congress of the European Pancreatic Club.
165. Pirisi M.,Falletti E.,Soardo G.,Fasbris C.,Vitulli D.,Toniutto P.,Fonda M.,Bortolotti N., Gonano F.,Bartoli E.:Blood lipids and efficacy of interferon in hepatitis C. Il Friuli Medico,Alpe Adria Journal of Medicine XLIX,suppl.2(1994),62.
166. Fabris C.,Pirisi M.,Falletti E.,Soardo G.,Toniutto P.,Vitulli D., Gonano F.,Bartoli E.:Soluble intercellular Adhesion Molecule 1 predicts serum concentration of markers of liver fibrosis.J.of Hepatol:21,suppl.1,(1994),s-90.
167. Fabris C.,Pirisi M.,Scott C., Avellini C., Soardo G.,Toniutto P.,Vitulli D.,Beltrami C.A.,Bartoli e.:Prevalence and impact on survival of occurrence of portal vein thrombosis in primary liver cancer.J.of Hepatol:,21.suppl.!,(1994),s-153.
168. Pirisi M.,Fabris C.,Toniutto P.,Vitulli D.,Soardo G.,Falletti E.,Gonano F.,Ferroni P.,Gasparini V.,Bartoli E.:Reactivity to B cell epitops within Hepatitis C virus.Cancer research,january 1,(1995) 111-114.
169. Toniutto P.,Pirisi M.,Fasbris C.,Falletti E.,Lombardelli T.,Soardo G.,Vitulli D.,Feroni P.,Gasparini V.,Gonano F.,Bartoli E.: Anti envelope antibodies,viraemia and

duration of abuse in anti-HCV positive drug addicts:Recenti Acquisizioni sulle Malattie Epatobiliari e Pancreatiche:aspetti clinici.Bolzano,7-8 aprile 1995.

170. Vitulli D.,Pirisi M.,Fabris C.,Soardo G.,Falleti E., Toniutto P.,Gonano F.,Bartoli E.:Soluble vascular cell Adhesion Molecule 18sCCAM-1) in patients with acute and chronic liver disease. Recenti Acquisizioni sulle Malattie Epatobiliari e Pancreatiche:aspetti clinici.Bolzano,7-8 aprile 1995
171. Falleti E.,Pirisi M.,Fabris C.,Carletti M.,Soardo G.,Toniutto P.,Vitulli D.,Del Forno M., Gonano F.,Bartoli E.:Impaired liver function as the major determinant of increased soluble V CAM-1 in acute and chronic liver disease.27° Congresso della Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica.Riva del Garda,3-6 ottobre 1995.
172. Pirisi M.,Fabris C.,Soardo G.,Cecchin E.,Toniutto P.,Bartoli E.:Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment.J.of Hepatol. 23,(1995)233.
173. Pirisi M., Fabris C., Soardo G., Falleti E., Gasparini D.,Vitulli D.,Toniutto P., Gonano F.,Bartoli E.:Hepatic release of erythropoietin induced by transarterial chemoembolization in patients with hepatocellular carcinoma.Hepatology 22,1 (1995) 148-152.
174. Pirisi M., Ferroni P., Fabris C., Toniutto P., Soardo G., Vitulli D., Gasparini V., Bartoli E: Anti envelope antibodies in anti hepatitis C virus (HCV)positive patients with and without liver disease.Infection,23(1995)28/24-32/28.
175. Vitulli D., Soardo G., Pirisi M., Falleti E.,Fabris C.,Del Forno M.,Bardus P.,Gonano F.,Bartoli E.:Increased soluble ICAM-1 levels and impaired delayed-type hypersensitivity skin tests in liver disease.It.J.Gastroenterol.,28,suppl 2 (1996)239.
176. Falleti E.,Pirisi M.,Fabris C.,Soardo G.,Vitulli D.,Toniutto P.,Bortolotti N.,Gonano F.,Bartoli E.: cICAM-1 parallels increase of CA 19-9 in cholestasis.Il Friuli Medico.Alpe Adria Journal of Medicine XLIX suppl.2/94-18.
177. Pirisi M.,Falleti E.,Soardo G.,Fabris C.,Vitulli D.,Toniutto P.,Fonda M.,Bortolotti N.,Gonano F.,Bartoli E.:Blood lipids and efficacy of interferon in hepatitis C. Il Friuli Medico.Alpe Adria Journal of Medicine XLIX suppl.2/94-62
178. Toniutto P., Pirisi C.,Scott C.,Soardo G.,Fabris C.,Avellini C.,Vitulli D.,Pezzeta F.,Beltrami C.A.,Bartoli E.:Sialoadenite associata ad epatopatia cronica HCV-relata:Differenze col sindrome di Sjögren: Attib del 3° Convegni su Attualità e Prospettive in Epatologia.Padova,26 ottobre 1993.
179. Pirisi M.,Ferroni P.,Fabris C.,Vitulli D.,Pezzetta F.,Soardo G.,Toniutto P.,Gasparini V.,Bartoli E.:Antibodies to epitopes of the hepatic C virus (HCV)

core region and hepatocellular carcinoma (HCC).J.of Hepatol:18, suppl.1 (1993) s 29

180. Pirisi M.,Fabris C.,Scott C.,Soardo G.,Avellini C.,Toniutto P.,Vitulli D.,Pezzetta F.,Beltrami A.C.,Bartoli E.:Sexual segregation of risk factors for steatosis in HCV related chronic liver disease.Biology,immunopathology and clinics of hepatitis viruses.Parma,3-5 giugno 1993.
181. Toniutto P.,Pirisi M.,Falletti E.,Fabris C.,Soardo G.,Vitulli D.,Hocza V.,Bartoli E.:Fosfolipasi A2 serica quale espressione di risposta di fase acuta in corso di epatopatie croniche:Attualità e prospettive in Epatologia:II Convegno Triveneto ,Padova,6 novembre 1992.
182. Toniutto P.,Soardo G.,Pirisi M.,Ferroni P.,Gasparini V.,Tisminentzky S.G.,Fabris C.,Pacco P.,Brusaferro S., Baralle F., Bartoli E.:Diagnosi di infezione da virus G, con metodica immunoenzimatica e PCR Padova,28 ottobre 1994,Atti del 4° convegno su “Attualità e Prospettive in Epatologia”
183. Avellini C., Scott C., Pirisi M., Soardo G., Toniutto P., Vitulli D., Pizzolito S., Rimondi G., Beltrami C.A. end Bartoli E.: Influence of sex on factor associated with steatosis in HCV-Related Chronic Liver Disease. Pathol Research and Practice 189, 6-7, 640-641 August 1993.
184. Pirisi M., Fabris C., Ceriello A., Soardo G., Giacomello R., Toniutto P., Vitulli D., Gonano F., Bartoli E. :Deficient antithrombinIII activity and enhanced fibrinolysis inpatients with liver disease: evidence against a cause-effect relationship. Acta Gastroenterol Belg, 58, 230-237, 1995.
185. Pirisi M., Soardo G., Falletti E., Fabris C., Toniutto P.,Vitulli D.,Dal Forno M.,Federico E.,Mattiuzzo M.,Agostinis P.,Maurizio R.,Gonano F.,Bartoli E.:Increase of soluble tumor necrosis receptor-1 after a single interferon alpha dose does not depend on release of interleukin-10 or tumor necrosis factor.PAMWAL 99(suppl 1)(1998)61.
186. Soardo G., Pirisi M.,Avellini C.,Scott C.,Toniutto P.,Fabris C.,Vitulli D.,Falletti E.,Federico E. et al.:HFE missense mutations,inflammatory index and stainable iron in chronic hepatitis C. PAMWAL 99(suppl 1)(1998)66.
187. Toniutto P.,Pirisi M.,Fabris C.,Lombardelli T.,Gasparini V.,Falletti E.,Ferroni P., Soardo G.,Vitulli D.,Gonano F.,Bartoli E.:Clearance of hepatitis C virus (HCV)antibody positive intravenous drug users.J.Hepatol.23,suppl.1(1995)c1/73.
188. Vitulli D., Patrone P., Pirisi M., Frattasio A., Fabris C., Soardo G.,Toniutto P.,De Francesco V.,Bartoli E.:Diagnostic value of cutaneous signs in liver disease.J.Hepatol.23,suppl.1(1995)c18/277.

189. Toniutto P., Pirisi M., Fabris C., Soardo G., Vitulli D., Pezzetta F., Bartoli E.: Sialoadenitis associated with HCV-related chronic liver disease differs from Sjögren syndrome (SS). *J. Hepatol.* 18, suppl 1 (1993) T-441
190. Del Forno M., Fallet E., Toniutto P., Soardo G., Fabris C., Pirisi M.: increase of sTNFR-1 after single interferon dose. International conference on interferons: biology and clinical applications. Venice, march 16-18, 1998.
191. Soardo G., Ceriello A., Pirisi M., Giacomello R., Fabris C., Hocza P., Toniutto P., Gonano f., Bartoli E.: Enhanced fibrinolysis in advanced liver disease: role of decreased coagulation inhibitors. *J. Hepatol* 16, suppl. 1 (1992) p1-58
192. Soardo G., Pirisi M., Ferraccioli G.F., Avellini C., Scott C., Fabris C. et al: Sialoadenitis associated with HCV related chronic liver disease differs from Sjögren syndrome. *Biology, immunopathology and clinic of Hepatitis viruses*, Parma, 3-5 giugno 1993
193. Aprile G., Agostinis P., Maurizio R., Soardo G., Pizzolito S., and Bartoli E. Bursting metastasis in thymic carcinoma. *Adv Clin Path*, 3, 35-41 (1999).
194. Pirisi M., Scott C.A., Avellini C., Toniutto P., Fabris C., Soardo G., Beltrami C.A., and Bartoli E. Iron deposition and progression of disease in chronic hepatitis C. *Am J Clin Pathol*, 113, 546-554, 2000.
195. Soardo G., Gasparini D., Agostinis P., Maurizio R., and Aprile G. Refractory chylous ascites in patient affected by Lymphangiomyomatosis responding to Denver Peritoneocaval shunt. Case Report. *Acta med Austriaca. Supplement* 49, p 25, 1999.
196. Aprile G., Agostinis P., Maurizio R., and Soardo G. Bursting metastasis in thymic carcinoma. Case report. *Acta med Austriaca. Supplement* 49 p 25, 1999
197. Soardo G., P. Agostinis, R. Maurizio, D. Casaccio e M. Caldato. Risultati e attuali protocolli di terapia antivirale nella epatite cronica HCV e HBV. Estratti del IX congresso "La crioglobulinemia mista, modello di malattia infettiva, infiammatoria e autoimmune: nuove prospettive. Pag 29. Udine 21-22 giugno 2002
198. R. Varutti, D. Donnini, R. Maurizio, F. Curcio, L.A. Sechi and G. Soardo. Alcohol induced endothelial dysfunction and oxidative stress in Heavy drinkers. *Alcohol and Alcoholism* 2003 vol 38(5) 525.
199. Donnini D., Varutti R., Basan I., Esposito W., Moretti M., Curcio F., Sechi L. e Soardo G. Disfunzione endoteliale e stress ossidativi indotte dall'alcol in un sistema in vitro di cellule endoteliali di aorta umana. *Alcologia supp.* Pp 20 (9) 2003.
200. Varutti R., Donnini D., Maurizio R., Casaccio D., Curcio F., Sechi L. e Soardo G. Effetti della disassuefazione alcolica sui principali parametri di disfunzione

endoteliale e di stress ossidativi in un gruppo di pazienti Heavy drinkers. *Alcologia supp.* Pp37(6) 2003.

201. Hjiazi K., Casaccio D., VARutti R., Ciano R., Soardo G., Sechi L., e Balestrieri M. Valutazione della personalità in un gruppo di pazienti alcolisti cronici ( Heavy drinkers). *Alcologia supp.* Pp 23 (9) 2003.
202. Agostinis P, BardusP., Di Piazza V., Soardo G., Avellini C. Sindrome da overlap: colangite sclerosante primitiva, colangite autoimmune, lichen simplex cutaneo. Attualità e prospettive in epatologia. Padova 24-25 novembre 2003 Atti pagina 197
203. Agostinis P., Di piazza V., Bardus P., Soardo G., Avellini C. Manganismo: causa di sindrome neurologica complessa nei pazienti affetti da cirrosi epatica con shunt-porto sistemico. Attualità e prospettive in epatologia. Padova 24-25 novembre 2003. Atti pagina 198
204. Soardo G. HCV and Autoimmunity.Epatite cronica C ed epatocarcinoma. Udine Soardo 2-3 aprile 2004 Atti pag. 75-79.
205. Soardo G., Pagano C, Esposito W, BAsan L, Domenis L, Federspil G, Vettor R, Sechi LA. Alterazione della concentrazione di adipokine seriche nella steatosi epatica di origine non alcolica (NAFLD). Atti convegno internazionale attualità e prospettive in epatologia PD 2004 p 173.
206. Quartuccio L., Soardo G., Romano G., Sacco S., Esposito W., De Marchi G., De Vita S. Treatamnent og Glomerulonephritis in Type II Mixed Cryoglobulinemia with Rituximab. *Arthritis and Rheumatism supp* ; 50:9;S235: 2004
207. Soardo G., Pagano C, Donnini D, Milocco C, Domenis L, Federspil G, Vettor R, Sechi LA. Adipokines in nonalcoholic fatty liver disease: a possible link between adipose tissue excess and liver damage. *Ann Ital Med Int* 2005; Vol 20 Supp 2.
208. Catena C, Baroselli S, Lapenna R, Novello M, Nadalini E, Soardo G., Cavarape A, Sechi LA. Fattori emergenti di rischio cardiovascolare in pazienti con iperaldosteronismo primitivo. *Ann It Med Int* 2005; 20 supp 2 p
209. Soardo G., Donnini D., Varutti R., Moretti M., Milocco C., Basan L., Esposito W., Casaccio D., Stel G., Catena C., Curcio F., Sechi LA. Le modificazioni dell'endotelio indotte dall'alcool sonomediate dallo stress ossidativo e sono rapidamente corrette dopo sospensione. *Ipertensione e Prevenzione Cardiovascolare* 2005; 12: p29.
210. Catena C, Baroselli S, Lapenna R, Novello M, Clussi G, Nadalini E, Soardo G., Cavarape A, Sechi LA. I nuovi fattori di rischi cardiovascolare nei pazienti con iperaldosteronismo primitivo. *Ipertensione prev cardiovasc.* 2005; vol 12 n°3

211. Soardo G., Pagano C., Esposito W., Basan L., Domenis L., Federspil G., Vettor R., Sechi LA. Serum adipokines levels in nonalcoholic fatty liver disease. J Hepatology 2005; 42 supp 2, p 253.
212. Soardo G., Donnini D, Milocco C, Varutti R, Basan L, Catena C, Sechi LA. Alcohol-induced endothelial changes are mediated by oxidative stress and are rapidly reversed after withdrawal. Ann Ital Int Med. 2005; vol 20 supp 2.
213. Soardo G., Pagano C., Donnini D., Pilon C., Dibenedetto A., Varutti R.m, Azzolini S., Olivieri M., Milocco C., Vettor R., Sechi LA. Circulationg and adipose tissue expression of Visfatin in non alcoholic fatty liver disease. Internal and Emergency Medicine 2006 1: supp 2 p 58s.
214. Soardo G., Pagano C., Donnini D., Milocco C., Basan L., De Silvestri D., Domenis L., Dibenedetto A., Vettor R., Sechi LA. Gli acidi grassi liberi alterano in vitro la funzine delle cellule endoteliali. Ruolo protettivo dell'adiponectina e implicazioni per la sindrome metabolica. Internal and Emergency Medicine 2006 1: supp 2 p 58s.
215. Soardo G., Donnini D, Domenis L, Milocco C, Federspil G, Vettor C, Varutti R, Sechi LA Pagano C. Valutazione dei valori plasmatici di adiponectina negli alcolisti Heavy drinkers prima e dopo periodo di astinenza. Incontro di gastroenterologia ed epatologia: Dal paziente alla ricerca ABS PD 2006 p 57.
216. Pagano C, Donnini D, Pilon C, Domenis L, Azzolini S, Olivieri M, Milocco C, Vettor R, Sechi LA, Soardo G. Espressione della visfatina circolante e nel tessuto adiposo nella non alcoholic fatty liver disease(NAFLD). Incontro di gastroenterologia ed epatologia: Dal paziente alla ricerca ABS PD 2006 p 37.
217. Soardo G., Pagano C., Donnini D., Pilon C., Domenis L., Azzolini S., Olivieri M., Milocco C., Vettor R., Sechi LA. Circulationg and adipose tissue expression of Visfatin in non alcoholic fatty liver disease. J Hepatology 2006 ; 44 supp 2 s 263-264.
218. Soardo G., Domenis L., Milocco C., Fedrspil G., Vettor R., Varutti R., Sechi LA., Pagano C. Valutazione dei valori plasmatici di Adiponectina negli alcolisti "heavy drinkers" prima e dopo periodo di astinenza. ABS book Incontri di gastroenterologia ed epatologia dal paziente alla ricerca Padova 2006 p 57.
219. Soardo G., Pagano C., Donnini D., Milocco C., Basan L., Domenis L., De Silvestri D., Cappello D., Vettor R., Sechi LA. Adiponectin protects against fatty acids-induced impairment of endothelial function in vitro. Implications for vascular dysfunction in non-alcoholic fatty liver disease. J Hepatology 2007; 44 supp 1 s 285.
220. Carderi I., Paternoster D., Soardo G., Azzaroli F., Mazzella G., Esposito W., Montagnani M., Marchesini D., Variola A., Rosa E., MDR3 mutation in a large

cohort of Italian women with intrahepatic cholestasis of pregnancy (ICP). *J Hepatology* 2007; 44 suppl 1 s 119.

221. Soardo G., Donnini D., Moretti M., Milocco C., Catena C., Sechi L.A. Effects of Zofenopril, Carvedilol, and Lacidipine on alcohol-induced responses in cultured human endothelial cells. *J Clin Hypertension* 2007; 9 suppl A 50.
222. Catena C., Chiuch A., Colussi G., La penna R., Nadalini E., Favret G., Cavarape A., Soardo G., Sechi LA. Association of a prothrombotic state with metabolic syndrome in essential hypertensive patients. *J Clin Hypertension* 2007; 9 suppl A 191.
223. Soardo G., Donnini D., Moretti M., Milocco C., Catena C., Sechi L.A. Effects of antihypertensive drugs on alcohol-induced functional responses of cultured human endothelial cells European Meeting Hypertension. S 239 2007.
224. G. Soardo., D Donnini, M Moretti, C Milocco, C Catena, LA Sechi. Farmaci antiipertensivi e risposta funzionale indotta dall'alcool in cellule endoteliali umane in coltura. *Ipertensione e prevenzione cardiovascolare*. Sept 2007 174.
225. Furlanut M., Franceschi L., Soardo G. Fluoxetine disposition in patients suffering from chronic hepatitis C treated with interferon alpha. 2008
226. G. Soardo, D. Donnini, C. Pagano, C. Milocco, L. Domenis, D. De Silvestri, D. Cappello, A.G. Di Benedetto, LA Sechi. Free fatty acids induce oxidative stress in HEPG2-Cell . Protective role of anti-oxidant substances and Adiponectin. *J Hepatology* 2008; 48 suppl 2 s 970.
227. Donnini D., Milocco C., Domenis L., De Silvestri D., Di Benedetto A., Cappello D., Pagano C., Vettor R., Sechi L.A., Soardo G. Elevated adiponectin levels in heavy drinkers are related to liver disease severity: Effects of alcohol withdrawal. *Digestive and liver disease* 40, 10 2008: A126.
228. Donnini D., Domenis L., De Silvestri D., Cappello D., Di Benedetto A., Carnelutti A., Sechi L.A., Soardo G. Beneficial effect of N-Acetylcysteine and glutathione on ammonia-induced glutamate accumulation in astrocyte cell culture. *J. of Hepatology*. Suppl. 1, Vol. 50 2009: 745.
229. Soardo G., Donnini D., Favaretto F., Boscaro A., Vettor R., Cappello D., Domenis L., Pagano C., Sechi L.A. Reduced FGF-21 expression in liver of patients with non alcoholic fatty liver disease. *Digestive and Liver Disease* 42, suppl. 1: S3 2010.
230. Soardo G., Driul A., Carnelutti A., Domenis L., Cappello D., De silvestri D., Marchesoni D., Sechi L.A., Donnini D. Intrahepatic cholestasis of pregnancy: A "in vivo" model of the hepatic clearance of adiponectin. *Journal of Hepatology* 52 suppl 1: S328 2010.

231. Soardo G., Franceschi L., Donnini D., Furlanut M., Sechi L. Treatment of chronic epatiti C with PEG-INF-alfa plus ribavirin doesn't alter fluoxetine disposal. *Digestive and Liver Disease* 42, suppl. 1: S44 2010
232. Colussi G., Donnini D., Catena C., Iogna Prat L., Carnelutti A., Di Fabio A., Soardo G., Sechi L.A. Evaluation of endothelial function in patients with non alcoholic fatty liver disease. *The Journal of Clinical Hupertension* 12: suppl 1 2010
233. Bonasia V., De Silvestri D., Carnelutti A., Donnini D., Soardo G., Sechi L.A. Proteinuria in paziente con MGUS. *Atti del Convegno di Attualità in Medicina Interna*: pp 61-62, Venezia 16 aprile 2010
234. Di Benedetto A., Cappello D., Cugini F., De Luca L., Donnini D., Soardo G., Sechi L.A. Calo ponderale, pan citopenia, rialzo transaminasi e decadimento neuro cognitivo nel paziente anziano. *Atti del Convegno di Attualità in Medicina Interna*: pp 75-76, Venezia 16 aprile 2010
235. Colussi G., Catena C., Donnini D., Iogna Prat L., Carnelutti A., Di Fabio A., Soardo G., Sechi L.A. Endothelial function in patients with non alcoholic fatty liver disease. *J. of Hypertension* vol 28 suppl A June 2010 pag 122
236. Colussi G., Catena C., Donnini D., Iogna Prat L., Carnelutti A., Di Fabio A., Soardo G., Sechi L.A. Evaluation of Endothelial function in patients with non-alcoholic fatty liver disease. *High Blood Pressure cardiovascular Prevention* vol 17, n° 3 pp 172
237. Colussi G., Catena C., Donnini D., Iogna Prat L., Carnelutti A., Di Fabio A., Soardo G., Sechi L.A. Evaluation of Endothelial function in patients with non-alcoholic fatty liver disease. The 23rd Scientific Meeting of the International Society of Hypertension, Vancouver 26-30/9/10.
238. Colussi G., Catena C., Donnini D., Iogna Prat L., Carnelutti A., Di Fabio A., Soardo G., Sechi L.A. Studio della funzione endoteliale in pazienti con steatosi epatica non alcolica. Ipertensione e prevenzione cardiovascolare p 166. XXVII Congresso Nazionale 30/9-3/10/10, Roma
239. Donnini D., Cappello D., Carnelutti A., Bonasia V., Pagano C., Vettor R., Favaretto F., Sechi L., Soardo G. effect of dietary and weigh loss on circulating and hepatic expression of fibroblsat growth factor-21 in non alcoholic steatohepatitis. *Digestive and Liver Disease* 43S: pp83 (2011)
240. Soardo G., Donnini D., Di Benedetto, Cappello D., Cugini F., Sechi L.A. Beneficial effect of N-Acetyl Cysteine on hepatic Encephalopathy. Proceeding Paper 2011
241. Barghini V, Marzano L, Bonasia V, Cappello D, Carnelutti A, De Luca L, Cugini F, Catena C, Sechi LA, Soardo G. Tissue Doppler imaging analysis, a new method



for the diagnosis of diastolic dysfunction in cirrhotic cardiomyopathy. Abstracts of the A.I.S.F. Annual Meeting 2012 /Digestive and Liver Disease 44S (2012), S1–S48

242. S. Bellentani, A. Brachetti, E. Dionigi, A. Fracanzani, G. Brandi, L. Miele, I. Rigato, G. Svegliati Baroni, G. Giannini, G. Cabibbo, F. Piscaglia, G. Soardo, F. Marra, F. Farinati, E. Villa, on behalf of the HCC-NASH Italian Group The emerging impact of HCC-NAFLD in Italy Abstracts of the A.I.S.F. Annual Meeting 2012 /Digestive and Liver Disease 44S (2012), S1–S48
243. D. Donnini, A. Carnelutti, G. Nadalutti, L. De Luca, D. Cappello, F. Cugini, S. Parlamento, A. Dibenedetto, D. De Silvestri, L. Sechi, G. Soardo. Hypolipidemic therapy vs diet in hypercholesterolemic patients affected by nonalcoholic steatohepatitis (NASH). Journal of Hepatology, Volume 56, Supplement 2, April 2012, Page S521.
244. A. Dibenedetto, D. Donnini, L. Domenis, D. De Silvestri, D. Cappello, A. Carnelutti, L. Veriello, G. Pauletto, L. Sechi, G. Soardo. Beneficial effect of N-Acetyl-Cysteine on hepatic encephalopathy : “in vivo and vitro study” Journal of Hepatology, Volume 54, Supplement 1, March 2011, Pages S241-S242
245. L. Valenti, B. Motta, G. Soardo, C. Bertelli, A. Sangiovanni, R. Rametta, P. Dongiovanni, M. Colombo, S. Fargion, A.L. Fracanzani 315 I148M PNPLA3 Polymorphism is associated with clinical features in patients with hepatocellular carcinoma. A J hepatology Volume 56, Supplement 2, Pages i-x, S1-S614 (April 2012)
246. V. Barghini, L. Marzano, V. Bonasia, D. Cappello, A. Carnelutti, L. De Luca, F. Cugini, C. Catena, L. Sechi, G. Soardo. Tissue doppler imaging analysis improve the sensibility and specificity in the diagnosis of diastolic dysfunction in cirrhotic cardiomyopathy. J hepatology Volume 56, Supplement 2, Pages i-x, S1-S614 (April 2012)
247. B. Donati, P. Dongiovanni, R. Rametta, A. Carnelutti, A.L. Fracanzani, G. Soardo, S. Fargion, L. Valenti. ENRICHMENT IN NOVEL RARE CODING VARIANTS OF TELOMERASE GENE IN HEPATOCELLULAR CARCINOMA PATIENTS WITH NASH RELATED CIRRHOSIS. Digestive and Liver Disease 02/2014; 46(supplement 1):e14-e15.
248. I. Bramuzzo, D. Cappello, V. Barghini, A. Carnelutti, V. Bonasia, G. Nadalutti, D. Donnini, L.A. Sechi, G. Soardo. SPLEEN STIFFNESS MEASUREMENT BY ARFI STRONGLY PREDICT THE OESOPHAGEAL VARICES STAGE AND BLEEDING PROBABILITY Digestive and Liver Disease 02/2014; 46(supplement 1 february 2014):e60
249. B. Donati, P. Dongiovanni, L. Miele, C. Rosso, S. Maier · S. Petta · M. Meroni L. De Luca · S. Grimaudo · R. Romagnoli · F. Colli · A. Craxi · A. Grieco · E. Bugianesi · S. Fargion · A.L. Fracanzani · G. Soardo · L. Valenti. [MBOAT7](#)

[locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver](#) Digestive and Liver Disease Volume 48, Supplement 1, Pages e1-e66 (10 February 2016).

250. PJ. Giraudi, SE. Gambaro, CM. Chackelevicius, M.Giuricin, LS. Crocè, D. Bonazza, G. Soardo, N. de Manzini, C.Tiribelli, S. Palmisano, N. Rosso. In silico identification and in vivo validation of non-invasive biomarkers for liver fibrosis. Journal of Hepatology vol 64, Supplement 2, pages S133-S942(april 2016)
251. L. De Luca, S. Mirabella, S. Maier, C. bianco, G. Soardo. Hepatitis C patients with any degree of portal hypertension are at risk to develop serious adverse effect to direct-acting antiviral therapy. Digestive and Liver Disease 48s(2016) e 233-e 239
252. F. Masutti, E. garlatti Costa, I. Crosatto, G. Soardo, M. Ghersetti, P. casarin, LS. Crocè, C. Tiribelli. Real life of DAAS for HCV infection in Friuli Venezia Giulia: Who, Why, What, how did we treated. Digestive and Liver Disease 48s(2016) e 233-e 239
253. I. Bramuzzo, A. Gerussi, S. Maier, C. Bianco, V. barghini, RS. Brizzi, A. Gonta, A. Uzzau, A. Vit, D. Donnini, LA.Sechi, G Soardo. Non adherence to AASLD-EASL guidelines for the management of hepatocellular carcinoma does not translate into worse outcome. ABS. EASL HCC Summit 2018.
254. I. Bramuzzo, A. Gerussi, S. Maier, C. Bianco, V. barghini, L.Scata, A. C.Laghi Pasini, A. Romanin, A. Vit, A. Uzzau, D. Donnini, LA.Sechi, G.Soardo. Evaluation of prognostic factors of overall survival and progression-free survival in patients with HCC. ABS. EASL HCC Summit 2018.
255. G.A. Baselli , M. Longo, M. Meroni, S. Pelusi , A.L. Fracanzani, G. Soardo, E. Bugianesi, R.Romagnoli, S. Petta , L. Miele , R.De Francesco, S. Fargion, P. Dongiovanni, L.Valenti. Functional characterization of a novel genetic variant predisposing to hepatocellular carcinoma development in nonalcoholic fatty liver disease. Abstracts / Digestive and Liver Disease 50(1S) (2018) 1–19  
<https://doi.org/10.1016/j.dld.2018.01.032>
248. S. Pelusi , G. Baselli , A. Pietrelli, P. Dongiovanni, M. Meroni, B. Donati, A.L. Fracanzani, R. Romagnoli, S. Petta , L. Miele, A. Grieco, E. Bugianesi, G. Soardo, R.De Francesco, S. Fargion, L. Valenti. Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Abstracts / Digestive and Liver Disease 50(1S) (2018) 20–4.  
<https://doi.org/10.1016/j.dld.2018.01.092>
249. S. Maier, S.L. Crocè, M.R. Buonocore, C. Pilon, S. Fargion, R. Vettor, L.A. Sechi, D. Donnini, C. Pagano, L. Valenti, G. Soardo. Role of SERPINB3 like serological and molecular biomarker into NASH development and progression. Abstracts / Digestive and Liver Disease 50(1S) (2018) 1–19.  
<https://doi.org/10.1016/j.dld.2018.01.037>

250. G. Baselli, A. Pietrelli, S. Pelusi, M. Meroni, A. L. Fracanzani, G. Soardo, E. , R. Romagnoli, S. Petta, L. Miele, S. Fargion, R. De Francesco, P. Dongiovanni and L. Valenti. Integrative Analysis of NGS Data Highlight a Genetic Variant in ATG7 Gene As a Novel Risk for Nonalcoholic Fatty Liver Disease Progression. Hepatology, nov 2018 Volume 68, Number 1 (Supp) Pag.357
251. S. Pelusi, G. A. Baselli, A. Pietrelli, P. Dongiovanni, B. Donati<sup>1</sup>, M. V. McCain, M. Meroni, A. L. Fracanzani, Renato R., S. Petta, A. Grieco, L. Miele, G. Soardo, E. Bugianesi, S. Fargion, A. Aghemo, C. Xing, S. Romeo, R. De Francesco, H. Reeves and L. Valenti, Inherited Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Hepatology, nov 2018 Volume 68, Number 1 (Supp) Pag.1011
252. Pelusi S, Baselli G, Cespiati A, Dongiovanni P, McCain MV, Meroni M, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, De Francesco R, Romeo S, Fracanzani AL, Reeves HL, Valenti L. "ATG7 genetic variant and defective autophagy: a novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus " Digestive and Liver Disease 51(1) e4-e5 2019
253. Pelusi S, Baselli G, Cespiati A, Dongiovanni P, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, De Francesco R, Romeo S, Reeves HL, Valenti L. "FRI-333-ATG7 genetic variant and defective autophagy: a novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus J Hepatology 70(1): e542 April 2019.
254. Cespiati A, Pelusi S, Maier S, Lombardi R, Baselli G, Dongiovanni P, Soardo G, Fracanzani AL, Valenti L. Risk of liver disease in first degree relatives of a patients with advanced NAFLD: initial data from an Italian cohort study. Digestive and Liver Disease 51 e 23 February 2019
255. Pelusi S, Pietrelli A, Baselli G, Dongiovanni P, Meroni M, Donati B, Fracanzani AL, Romagnoli R, Petta S, Miele L, Grieco A, Bugianesi E, Soardo G, De Francesco R, Fargion S, Valenti L. Role of rare pathogenetic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. J of Hepatology 68(1) e330-s331 April 2018
256. Baselli G, Pietrelli A, Pelusi S, Meroni M, Fracanzani AL, Soardo G, Bugianesi E, Romagnoli R, Petta S, Miele L, Fargion S, Dongiovanni P, Valenti L. Integrative analysis of NGS data highlight a genetic variant in ATG7 gene as a novel risk factor for nonalcoholic fatty liver disease progression. Journal of Hepatology 68(1) s334 s335 April 2018.
256. Longo M, Meroni M, Erconi V, Carli F, Macchi C, Ronchi D, Sabatini S, Paolini E, De Caro ER, Alisi A, Miele L, Soardo G, Comi GP, Valenti L, Ruscica M, Fracanzani AL, Gastaldelli A, Dongiovanni P. TM6SF2/PNPLA3/MBOAT/ loss-

of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models. *Digestive and Liver Disease* 53 : S27-S28 March 2021.

257. Pelusi S, Malvestiti F, Baselli G, Bianco C, Santaniello C, Santoro L, **Soardo G**, D'Ambrosio R, Barcellini W, Miozzo M, Prati D, Valenti L. Whole exome sequencing for the diagnosis of rare genetic conditions in patients with unexplained liver disease and complex clinical presentation. *Digestive and Liver Disease* 53 : S20 March 2021.
258. Baselli G, Pelusi S, Ciociola E, Dongiovanni P, Maggioni M, Tavaglione F, Bianco C, Mancina RM, Santoro L, Petta S, Miele L, Vespasiani Gentilucci U, Federico A, Bugianesi E, Fracanzani AL, Reeves H, **Soardo G**, Miozzo M, EPIDEMIC Study Investigators, Prati D, Romeo S, Valenti L. Rare common ATG7 variants predispose to severe fatty liver disease. *Digestive and Liver Disease* 53: S26-S27 March 2021
259. Marica Meroni, Miriam Longo, Erika Paolini, E.R. De caro, Anna Alisi, Luca Miele, **Giorgio Soardo**, Luca valenti, Anna Ludovica Fracanzani, Paola Dongiovanni. The PSRC1 rs599839 a>G variant disentangle the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients. *Digestive and Liver Disease* 53:S32 <http://dx.doi.org/10.1016/j.dld.2020.12.080>
260. Baselli G, Pelusi S, Ciociola E, Dongiovanni P, Maggioni M, Bianco C, Tavaglione F, Cespiati A, mancina RM, Malvestiti F, Costanza J, D'Ambrosio R, petta S, Miele L, vespasiani U, Federico A, Pihlajamäki, Bugianesi E, Fracanzani AL, Reeves H, **Soardo G**, Prati D, EPIDEMIC Study Investigators, Romeo S, Valenti L. Rare Atg7 variants predispose to severe fatty liver disease. *SSRN Electronic Journal*. January 2021
261. Bianco C, Pelusi S, Baselli G, Zanoni I, Taliento A, Dongiovanni P, Rametta R, Borroni V, Federico A, Vespasiani Gentilucci U, D'Ambrosio R, Bugianesi E, Petta S, Miele L, Reeves HL, Fracanzani AL, **Soardo G**, Prati D, Valenti L. A polygenic risk score for progressive non-alcoholic fatty liver disease risk stratification *J Hepatology* 73: S13-S14 August 2020
262. Bianco C, Pelusi S, Baselli G, Zanoni I, Taliento A, Dongiovanni P, Rametta R, Borroni V, Federico A, Vespasiani Gentilucci U, D'Ambrosio R, Bugianesi E, Petta S, Miele L, Reeves HL, Fracanzani AL, **Soardo G**, Prati D, Valenti L. Noninvasive risk stratification in non-alcoholic fatty liver disease: a polygenic risk score. *Digestive and Liver Disease* 52: e9-e10 February 2020

